CN116723837B - Cdk2抑制剂的固体形式 - Google Patents

Cdk2抑制剂的固体形式

Info

Publication number
CN116723837B
CN116723837B CN202180086069.9A CN202180086069A CN116723837B CN 116723837 B CN116723837 B CN 116723837B CN 202180086069 A CN202180086069 A CN 202180086069A CN 116723837 B CN116723837 B CN 116723837B
Authority
CN
China
Prior art keywords
cancer
crystalline
ppm
values
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180086069.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116723837A (zh
Inventor
F·曹
K·F·德布亚赛
M·希伯来茵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN116723837A publication Critical patent/CN116723837A/zh
Application granted granted Critical
Publication of CN116723837B publication Critical patent/CN116723837B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cereal-Derived Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180086069.9A 2020-12-24 2021-12-21 Cdk2抑制剂的固体形式 Active CN116723837B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130530P 2020-12-24 2020-12-24
US63/130,530 2020-12-24
PCT/IB2021/062082 WO2022137106A1 (en) 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor

Publications (2)

Publication Number Publication Date
CN116723837A CN116723837A (zh) 2023-09-08
CN116723837B true CN116723837B (zh) 2026-05-26

Family

ID=79283019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086069.9A Active CN116723837B (zh) 2020-12-24 2021-12-21 Cdk2抑制剂的固体形式

Country Status (10)

Country Link
US (1) US20240076287A1 (enExample)
EP (1) EP4267563A1 (enExample)
JP (2) JP2024503235A (enExample)
KR (1) KR20230122100A (enExample)
CN (1) CN116723837B (enExample)
AU (1) AU2021404974B2 (enExample)
CA (1) CA3206153A1 (enExample)
MX (1) MX2023007699A (enExample)
TW (1) TWI823213B (enExample)
WO (1) WO2022137106A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CN118679150A (zh) * 2022-01-27 2024-09-20 益方生物科技(上海)股份有限公司 Cdk2抑制剂及其制备方法和用途
WO2024046443A1 (en) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Macrocyclic compounds as selective cdk inhibitors
WO2025191482A1 (en) 2024-03-15 2025-09-18 Pfizer Inc. Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Also Published As

Publication number Publication date
MX2023007699A (es) 2023-07-10
KR20230122100A (ko) 2023-08-22
TW202233606A (zh) 2022-09-01
AU2021404974A1 (en) 2023-07-06
JP2026123057A (ja) 2026-07-29
AU2021404974B2 (en) 2024-11-28
WO2022137106A1 (en) 2022-06-30
TWI823213B (zh) 2023-11-21
JP2024503235A (ja) 2024-01-25
EP4267563A1 (en) 2023-11-01
CN116723837A (zh) 2023-09-08
CA3206153A1 (en) 2022-06-30
AU2021404974A9 (en) 2025-04-10
US20240076287A1 (en) 2024-03-07

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096368

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant